23: Cost-Effectiveness of Sabr in Oligometastatic Cancer: An Economic Analysis Based on Long-Term Results of the SABR-Comet Randomized Trial. (October 2021) - Qu, Melody; Chen, Yujie; Zaric, Gregory; Senan, Suresh; Olson, Robert; Harrow, Stephen; John-Baptiste, Ava; Gaede, Stewart; Mulroy, Liam; Schellenberg, Devin; Senthi, Sashendra; Swaminath, Anand; et al.